Pro Medicus revenue grew 33% annually to $162M, driven by the Visage radiology platform. Net profit hit $83M, ROE 50.7%. Rio Tinto paid a 6.8% dividend yield on a 23.9% debt ratio.
Pro Medicus Ltd posted revenue of $162 million in its fiscal 2024 year, the company said. That figure represents a compound annual growth rate of 33.4% since fiscal 2021, when revenue sat at $33 million.
Net profit climbed to $83 million from $31 million over the same stretch.
The growth is tied to the Visage platform, which lets radiologists view large medical images on mobile devices. Hospitals and imaging centers are signing up to speed up diagnostic decisions, the company said. Visage handles the heavy image files generated by X-rays and other scans, allowing remote interpretation without the lag that used to force radiologists to work from a fixed workstation.
Return on equity for fiscal 2024 came in at 50.7%. That metric matters for a technology company because it shows how much profit the business generates from the equity shareholders have put in. An ROE above 20% generally signals efficient use of capital.
Pro Medicus was founded in 1983 and sells Radiology Information Systems and Picture Archiving and Communication Systems to healthcare providers globally. The software handles patient scheduling, billing, and rapid image interpretation. The company's customer base stretches across hospitals and imaging centers worldwide.
Rio Tinto Ltd, by contrast, reported a debt-to-equity ratio of 23.9% for calendar 2024, the company said. That means the miner carries roughly four dollars of equity for every dollar of debt. The company paid an average dividend yield of 6.8% per year since 2020. Its return on equity for calendar 2024 was 20.3%, above the 10% threshold investors typically expect from a mature business.
Rio operates four business units: Aluminium, Copper & Diamonds, Energy & Minerals, and Iron Ore. Iron ore, the key component in steelmaking, is the largest export by revenue. That concentration means the company's earnings swing with commodity prices, a fact investors have to weigh against the dividend yield.
Pro Medicus trades on the ASX under ticker PME. Rio Tinto trades under RIO. BHP Group Ltd, the world's largest mining company by market cap, is Rio's primary peer in the sector.
The two companies sit at opposite ends of the lifecycle spectrum. PME is a growth-stage technology firm reinvesting earnings into software development and sales. RIO is a mature miner returning cash to shareholders through dividends. The metrics that matter for each reflect that difference: revenue growth and ROE for PME, debt levels and yield for RIO.
These figures provide a snapshot, not a full valuation. Investors should examine cash flow, competitive positioning, and industry trends before making a decision.
Pro Medicus shares last traded at levels that imply a market capitalisation roughly 50 times fiscal 2024 net profit. That multiple reflects the 33% revenue growth rate. Whether the company can sustain that pace as the addressable market matures is the open question the numbers don't answer.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.